We launched COVID Vaccine Facts, a new website with scientific and evidence-based information related to the COVID-19 vaccine development process. More details below, plus a look at the benefits of biotech crops. (663 words, 3 minutes, 18 seconds)
BIO launched a new website to help patients and their families understand and enroll in clinical trials—we have details. Plus, BIO weighed in on today’s House Agriculture Committee hearing on America’s renewable economy, and we may soon have an…
BIO launched an important new agenda to eliminate racial disparities in the industry and health care delivery. We’ve got the details, in around 670 words, just under 4 minutes.
Congratulations to BIO member Moderna on the emergency use authorization of your COVID-19 vaccine, the second vaccine to be authorized for use in the United States! These vaccines are safe and effective—but some Americans remain hesitant to get them. We discuss why and how we can tackle it, as well as take a look at what’s needed to grow the bioeconomy moving forward. (920 words, 4 minutes, 36 seconds)
Yesterday, an FDA independent advisory panel voted to endorse Moderna’s COVID-19 vaccine, clearing the way for emergency use authorization as soon as today. Meanwhile, we’re taking a look at the payroll R&D tax credit, Washington State’s plans for a low-carbon fuel standard, and whether the federal government will shut down tonight. (767 words, 3 minutes, 50 seconds)
The FDA Vaccines and Related Biological Products Advisory Committee meets today to discuss emergency use authorization of the Moderna COVID-19 vaccine. In other news, we look at new data on health care spending and the future of gene editing. (916 words, 4 minutes, 34 seconds)
COVID-19 vaccines are here—but how do we ensure people will get them when it’s their turn? BIO’s Dr. Michelle McMurry-Heath discussed this on CNN. Meanwhile, 2021 is shaping up to be a critical year in the war on climate change, so we take a look at the many ways gene editing can contribute. (834 words, 4 minutes, 10 seconds)
The emergency use authorization of a COVID-19 vaccine less than one year after the virus was identified is an amazing feat—but attempts to weaken IP protections could undermine this kind of innovation in the future. We explain why, plus look at how one company is successfully marketing its GM apples to consumers. (871 words, 4 minutes, 20 seconds)
It’s a happy Monday indeed with Pfizer-BioNTech vaccine doses on their way to every U.S. state and territory. Meanwhile, ICYMI in the midst of all the vaccine excitement, Bayh-Dole turned 40 and Congress passed the defense spending bill with a boost for the bioeconomy. (1,000 words, 5 minutes)
It’s Friday. Congress is working to avoid a government shutdown today. Meanwhile, we have a recap of yesterday’s FDA advisory committee meeting on the Pfizer-BioNTech vaccine as well as details of a new group working to advance Black professionals in the agriculture industry. (727 words, 3 minutes, 38 seconds)
